提炼
Vascular involvement in coronavirus disease 2019 (COVID-19) has been suggested by several observations, such as the high rate of pulmonary embolism [1], the prothrombotic state and the proinflammatory biological profile [2, 3], as well as the pathological findings of severe endothelial injury and diffuse thrombosis [4]. Dual-energy computed tomography (DECT) allows specific imaging of the iodinated contrast agent distribution within the lung, which has been demonstrated as a surrogate marker of lung perfusion [5, 6]. Therefore, our goal was to assess体内通过使用DECT并确定血管变化在疾病过程中是否有所不同,肺部19009肺炎患者的肺微血管受累。
抽象的
In COVID-19 pneumonia, dual-energy computed tomography has shown two patterns of lung perfusion along the course of the disease: an increase in perfusion blood volume (PBV) with ground-glass opacities and a decrease in PBV with consolidationhttps://bit.ly/2zh0xci
致谢
我们感谢Valerie Leitman(里昂大学)contributions to manuscript editing, and Adeline Mansuy (Hospices civils de Lyon) for the research proposal submission.
Footnotes
Conflict of interest: S. Si-Mohamed reports personal fees for consultancy from Boehringer Ingelheim and non-financial support for meeting attendance from Guerbet, outside the submitted work.
Conflict of interest: N. Chebib reports non-financial support for meeting attendance from CSL Behring, Actelion, GSK, Boehringer Ingelheim, Roche and MSD, outside the submitted work.
利益冲突:Sigovan M.没有什么可披露的。
利益冲突:L。Zumbihl没有什么可披露的。
Conflict of interest: S. Turquier has nothing to disclose.
利益冲突:S。Boccalini没有什么可披露的。
利益冲突:L。Boussel无话可说。
Conflict of interest: J-F. Mornex reports grants, personal fees and non-financial support from CSL Behring and LFB, personal fees and non-financial support from Actelion, personal fees from Roche, Boehringer Ingelheim, GSK, Novartis, Chiesi and Elivie, outside the submitted work.
利益冲突:V。Cottin报告顾问委员会工作和讲座的个人费用,以及非财务支持,以实现Actelion的出席,赠款,咨询和讲座的个人费用以及非金融支持,以实现Boehringer Ingelheim的会议,咨询委员会和数据监测委员会的费用,拜耳/MSD和加拉帕戈斯的工作,咨询委员会工作的个人费用以及诺华的讲座,数据监测和指导委员会工作的个人费用,咨询和讲座以及非财务支持,以召集参加会议的支持Roche/Promedior,Sanofi和Astrazeneca的讲座的个人费用,Celegene和Galecto的数据监测委员会工作的个人费用,Shionogi的顾问委员会工作的个人费用,在提交的工作之外的纤维肌指导委员会的个人费用,指导委员会的个人费用。
利益冲突:P。Douek没有什么可披露的。
- Received2020年7月2日。
- 公认September 2, 2020.
- 版权所有©ERS 2020。
此版本是根据创意共享归因于非商业许可4.0的条款分发的。